ID   Hu1734
AC   CVCL_8451
SY   Hu 1734; HU 1734
DR   BioSample; SAMN03151654
DR   cancercelllines; CVCL_8451
DR   Wikidata; Q54896693
RX   PubMed=7905254;
RX   PubMed=20143388;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a HCV-29 derivative (PubMed=7905254; PubMed=20143388).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00128.
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Val (c.1406G>T); ClinVar=VCV000044803; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Gln55Ter (c.163C>T); ClinVar=VCV000048808; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_8228 ! HCV-29
SX   Male
AG   Adult
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 24
//
RX   PubMed=7905254;
RA   Christensen B., Hansen C., Kieler J., Schmidt J.;
RT   "Identity of non-malignant human urothelial cell lines classified as
RT   transformation grade I (TGrI) and II (TGrII).";
RL   Anticancer Res. 13:2187-2191(1993).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//